At the University of Perugia, the team coordinated by Stefano Fiorucci further deepened the concept of dysbiosis with the aim to find out strategies that can improve the prognosis in patients with chronic inflammatory bowel diseases (IBD). The research team from the Department of Biomedical and Surgical Sciences analyzed the relationship between dysbiosis and inflammatory bowel disease, to support the concept that a defective immune reaction to bacterial antigens may have a pathogenic role in the development of disease. For this purpose, a new probiotic formulation was tested in an IBD mouse model by combining four probiotics (Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium breve, Bifidobacterium animalis subsp. lactis) with Bacillus subtilis, a Gram-positive bacterium.

Chemically-induced IBD mice were divided into three groups: one group was administered only with B. subtilis, the second group with the De Simone Formulation, and the third one was supplemented with the new formulation containing the five bacterial strains. The latter, which included Bacillus subtilis, showed to be effective in reducing the development of the signs and symptoms of colitis, and decreasing the expression of pro-inflammatory mediators, such as Il-6 and TNF- alpha. Furthermore, the bacterial combination also increased the expression of Il-10 mRNA and the concentration of T-reg lymphocytes.

This research highlights the enhancement of B. subtilis thanks to the addition of selected lactobacilli and bifidobacteria, or vice versa, the enhancement of lactobacilli and bifidobacteria with the addition of B. subtilis, showing new opportunities for intellectual protection of probiotic formulations.

To better understand the research strategy, Fiorucci explains: “Alteration in the composition of the microbiota is commonly detected in patients with IBD, especially in Crohn’s disease. This evidence supports the concept that unregulated immune reaction due to bacterial antigens plays a triggering role in the pathogenesis of these pathologies. Consequently, the gut microbiota represents an important therapeutic target in these disorders and can be modulated by this new bacterial formulation.”

Pr De Simone, About

Biagioli M et al. Nutrients  2020 Jun 30;12(7):E1945. doi: 10.3390/nu12071945

Share this article!

Categories: DSF, IBD, Probiotics

Keep connected, Subscribe

Probiotixx

The Letter of Probiotics

Probiotixx

The Letter of Probiotics

No spamming, no advertising. Science.

Subscribe to Pr De Simone’s blog. Get his latest analysis on the ever-evolving field of probiotics and their involvement in cutting-edge therapies.